Trevi Therapeutics (TRVI) vs Zenas BioPharma (ZBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Trevi Therapeutics (TRVI) has outperformed Zenas BioPharma (ZBIO) over the past year, gaining 30.6% versus a gain of 1.3%. Trevi Therapeutics is the larger company by market cap ($1.83 billion vs $1.71 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TRVI | ZBIO |
|---|---|---|
| Share price | $12.83 | $26.24 |
| Market cap | $1.83B | $1.71B |
| 1-day change | -2.40% | -6.88% |
| YTD return | +2.44% | -27.73% |
| 1-year return | +30.60% | +1.31% |
| 5-year return | +894.19% | — |
| EPS (TTM) | $-0.35 | $-9.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $10.00M |
| Revenue growth (YoY) | — | +100.00% |
| Net income (latest FY) | $-42.76M | $-377.74M |
| Operating margin | — | -3830.57% |
| Net margin | — | -3777.37% |
| 52-week high | $20.22 | $44.60 |
| 52-week low | $9.28 | $13.50 |
| Distance from 52-week high | -36.57% | -41.17% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +119.73% | +82.47% |
| Average volume | 1.95M | 735.12K |
| Shares outstanding | 142.48M | 65.18M |
| Employees | 34 | 167 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TRVI has outperformed ZBIO by 29.3 percentage points over the past year.
About Trevi Therapeutics
TRVI stock →Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
About Zenas BioPharma
ZBIO stock →Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Health Care · Biotechnology: Pharmaceutical Preparations · 167 employees
TRVI vs ZBIO FAQ
Which is bigger, Trevi Therapeutics or Zenas BioPharma?
Trevi Therapeutics (TRVI) is larger, with a market capitalization of $1.83B compared with $1.71B for Zenas BioPharma (ZBIO).
Which stock has performed better over the past year, TRVI or ZBIO?
TRVI returned +30.60% over the past 12 months, compared with +1.31% for ZBIO (price return, excluding dividends). Past performance does not predict future results.
Are Trevi Therapeutics and Zenas BioPharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.